Loading...

Natalia Jura, PhD

Title(s)Associate Professor, Cardiovascular Research Inst
SchoolSchool of Medicine
Phone415-514-1133
ORCID ORCID Icon0000-0001-5129-641X Additional info
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    The structural and functional basis of MET exon 14 activation and acquired drug resistance
    NIH/NCI R01CA230263Apr 1, 2019 - Mar 31, 2024
    Role: Principal Investigator
    FASEB SRC Protein Phosphorylation Networks in Health and Disease
    NIH/NCI R13CA232438Jul 6, 2018 - Jul 5, 2019
    Role: Principal Investigator
    Structural and Functional Studies of HER Receptor Tyrosine Kinases
    NIH/NIGMS R01GM109176Sep 1, 2014 - Aug 31, 2019
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Agnew C, Liu L, Liu S, Xu W, You L, Yeung W, Kannan N, Jablons D, Jura N. The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region. J Biol Chem. 2019 Sep 13; 294(37):13545-13559. PMID: 31341017.
      View in: PubMed
    2. Lopez ML, Lo M, Kung JE, Dudkiewicz M, Jang GM, Von Dollen J, Johnson JR, Krogan NJ, Pawlowski K, Jura N. PEAK3/C19orf35 pseudokinase, a new NFK3 kinase family member, inhibits CrkII through dimerization. Proc Natl Acad Sci U S A. 2019 Jul 30; 116(31):15495-15504. PMID: 31311869.
      View in: PubMed
    3. Kung JE, Jura N. Prospects for pharmacological targeting of pseudokinases. Nat Rev Drug Discov. 2019 07; 18(7):501-526. PMID: 30850748.
      View in: PubMed
    4. Erron W. Titus, Frederick H. Deiter, Chenxu Shi, Julianne Wojciak, Melvin Scheinman, Natalia Jura, Rahul C. Deo. The structure of a calsequestrin filament reveals mechanisms of familial arrhythmia. bioRxiv. 2019 Jun 15; 672303.
      View in: Publisher Site
    5. Diwanji D, Thaker T, Jura N. More than the sum of the parts: Toward full-length receptor tyrosine kinase structures. IUBMB Life. 2019 06; 71(6):706-720. PMID: 31046201.
      View in: PubMed
    6. Ruiz K, Thaker TM, Agnew C, Miller-Vedam L, Trenker R, Herrera C, Ingaramo M, Toso D, Frost A, Jura N. Functional role of PGAM5 multimeric assemblies and their polymerization into filaments. Nat Commun. 2019 01 31; 10(1):531. PMID: 30705304.
      View in: PubMed
    7. Kung JE, Jura N. The pseudokinase TRIB1 toggles an intramolecular switch to regulate COP1 nuclear export. EMBO J. 2019 02 15; 38(4). PMID: 30692133.
      View in: PubMed
    8. Frazier NM, Brand T, Gordan JD, Grandis J, Jura N. Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene. 2019 03; 38(11):1936-1950. PMID: 30390071.
      View in: PubMed
    9. Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 2018 11 12; 34(5):792-806.e5. PMID: 30449325.
      View in: PubMed
    10. Mishra R, Alanazi S, Yuan L, Solomon T, Thaker TM, Jura N, Garrett JT. Activating HER3 mutations in breast cancer. Oncotarget. 2018 Jun 12; 9(45):27773-27788. PMID: 29963236.
      View in: PubMed
    11. Liang SI, van Lengerich B, Eichel K, Cha M, Patterson DM, Yoon TY, von Zastrow M, Jura N, Gartner ZJ. Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras. Cell Rep. 2018 03 06; 22(10):2593-2600. PMID: 29514089.
      View in: PubMed
    12. Liu L, Thaker TM, Freed DM, Frazier N, Malhotra K, Lemmon MA, Jura N. Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23. Structure. 2018 02 06; 26(2):270-281.e4. PMID: 29358026.
      View in: PubMed
    13. Neben CL, Lo M, Jura N, Klein OD. Feedback regulation of RTK signaling in development. Dev Biol. 2019 03 01; 447(1):71-89. PMID: 29079424.
      View in: PubMed
    14. Agnew C, Jura N. Switching on BTK-One Domain at a Time. Structure. 2017 10 03; 25(10):1469-1470. PMID: 28978404.
      View in: PubMed
    15. van Lengerich B, Agnew C, Puchner EM, Huang B, Jura N. EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms. Proc Natl Acad Sci U S A. 2017 04 04; 114(14):E2836-E2845. PMID: 28320942.
      View in: PubMed
    16. Kung JE, Jura N. Structural Basis for the Non-catalytic Functions of Protein Kinases. Structure. 2016 Jan 05; 24(1):7-24. PMID: 26745528.
      View in: PubMed
    17. Michael N, Jura N. Src defines a new pool of EGFR substrates. Nat Struct Mol Biol. 2015 Dec; 22(12):945-7. PMID: 26643845.
      View in: PubMed
    18. Kovacs E, Das R, Wang Q, Collier TS, Cantor A, Huang Y, Wong K, Mirza A, Barros T, Grob P, Jura N, Bose R, Kuriyan J. Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor. Mol Cell Biol. 2015 Sep 01; 35(17):3083-102. PMID: 26124280.
      View in: PubMed
    19. Dániel Süveges, Natalia Jura. Structural Features of the Kinase Domain. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. 2015 Jan 1; 195-223.
      View in: Publisher Site
    20. N. Jura, P. Littlefield, A. M. VanHook. Science Signaling Podcast: 2 December 2014. Science Signaling. 2014 Dec 2; 7(354):pc31-pc31.
      View in: Publisher Site
    21. Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Sci Signal. 2014 Dec 02; 7(354):ra114. PMID: 25468994.
      View in: PubMed
    22. Murphy JM, Zhang Q, Young SN, Reese ML, Bailey FP, Eyers PA, Ungureanu D, Hammaren H, Silvennoinen O, Varghese LN, Chen K, Tripaydonis A, Jura N, Fukuda K, Qin J, Nimchuk Z, Mudgett MB, Elowe S, Gee CL, Liu L, Daly RJ, Manning G, Babon JJ, Lucet IS. A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. Biochem J. 2014 Jan 15; 457(2):323-34. PMID: 24107129.
      View in: PubMed
    23. Peter Littlefield, Mark M. Moasser, Natalia Jura. Regulation of the HER3/ErbB3 Pseudokinase Domain by an ATP-Competitive Inhibitor. Biophysical Journal. 2014 Jan 1; 106(2):523a.
      View in: Publisher Site
    24. Bettina van Lengerich, Bo Huang, Natalia Jura. Single Molecule Imaging of Human Epidermal Growth Factor Receptors. Biophysical Journal. 2014 Jan 1; 106(2):239a.
      View in: Publisher Site
    25. Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell. 2013 Oct 14; 24(4):438-49. PMID: 24135280.
      View in: PubMed
    26. Littlefield P, Jura N. EGFR lung cancer mutants get specialized. Proc Natl Acad Sci U S A. 2013 Sep 17; 110(38):15169-70. PMID: 24023066.
      View in: PubMed
    27. Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell. 2011 Apr 08; 42(1):9-22. PMID: 21474065.
      View in: PubMed
    28. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A. 2009 Dec 22; 106(51):21608-13. PMID: 20007378.
      View in: PubMed
    29. Natalia Jura, Nicholas F. Endres, Kate Engel, Sebastian Deindl, Rahul Das, Meindert H. Lamers, David E. Wemmer, Xuewu Zhang, John Kuriyan. Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment. Journal of End-to-End-testing. 2009 Aug 7; 138(3):604-604.
      View in: Publisher Site
    30. Natalia Jura, Nicholas F. Endres, Kate Engel, Sebastian Deindl, Rahul Das, Meindert H. Lamers, David E. Wemmer, Xuewu Zhang, John Kuriyan. Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment. Journal of End-to-End-testing. 2009 Aug 7; 138(33):604-604.
      View in: Publisher Site
    31. Natalia Jura, Nicholas F. Endres, Kate Engel, Sebastian Deindl, Rahul Das, Meindert H. Lamers, David E. Wemmer, Xuewu Zhang, John Kuriyan. Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment. Cell. 2009 Aug 1; 138(3):604.
      View in: Publisher Site
    32. Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell. 2009 Jun 26; 137(7):1293-307. PMID: 19563760.
      View in: PubMed
    33. Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature. 2007 Nov 29; 450(7170):741-4. PMID: 18046415.
      View in: PubMed
    34. Jura N, Bar-Sagi D. Mapping cellular routes of Ras: a ubiquitin trail. Cell Cycle. 2006 Dec; 5(23):2744-7. PMID: 17172849.
      View in: PubMed
    35. Archer H, Jura N, Keller J, Jacobson M, Bar-Sagi D. A mouse model of hereditary pancreatitis generated by transgenic expression of R122H trypsinogen. Gastroenterology. 2006 Dec; 131(6):1844-55. PMID: 17087933.
      View in: PubMed
    36. Jura N, Scotto-Lavino E, Sobczyk A, Bar-Sagi D. Differential modification of Ras proteins by ubiquitination. Mol Cell. 2006 Mar 03; 21(5):679-87. PMID: 16507365.
      View in: PubMed
    37. Kilarski WW, Jura N, Gerwins P. An ex vivo model for functional studies of myofibroblasts. Lab Invest. 2005 May; 85(5):643-54. PMID: 15723087.
      View in: PubMed
    38. Mezyk-Kopec R, Bzowska M, Potempa J, Bzowska M, Jura N, Sroka A, Black RA, Bereta J. Inactivation of membrane tumor necrosis factor alpha by gingipains from Porphyromonas gingivalis. Infect Immun. 2005 Mar; 73(3):1506-14. PMID: 15731048.
      View in: PubMed
    39. Jura N, Archer H, Bar-Sagi D. Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Res. 2005 Jan; 15(1):72-7. PMID: 15686632.
      View in: PubMed
    40. Bzowska M, Jura N, Lassak A, Black RA, Bereta J. Tumour necrosis factor-alpha stimulates expression of TNF-alpha converting enzyme in endothelial cells. Eur J Biochem. 2004 Jul; 271(13):2808-20. PMID: 15206946.
      View in: PubMed
    41. Kilarski WW, Jura N, Gerwins P. Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. Exp Cell Res. 2003 Nov 15; 291(1):70-82. PMID: 14597409.
      View in: PubMed
    42. Hall AB, Jura N, DaSilva J, Jang YJ, Gong D, Bar-Sagi D. hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl. Curr Biol. 2003 Feb 18; 13(4):308-14. PMID: 12593796.
      View in: PubMed